Linker Information
General Information of This Linker
| Linker ID |
LIN0ZUUJH
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
L30 linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C173H312N18O73
|
|||||
| Isosmiles |
COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(N(C)CC(C=C(NC([C@@H](NC([C@@H](NC([C@@H](NC(OCC1=CN(N=N1)CC(N[C@H](C(N[C@H](C(NC2=CC=C(C(CN(C(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)=C2)O)=O)CCCNC(N)=O)=O)C(C)C)=O)=O)CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCN3C(C=CC3=O)=O)=O)=O)C(C)C)=O)CCCNC(N)=O)=O)C=C4)=C4O)=O
|
|||||
| InChI |
InChI=1S/C173H312N18O73/c1-146(2)164(169(203)181-153(14-11-26-177-171(174)205)166(200)179-150-16-18-156(192)148(139-150)141-188(5)160(196)23-30-211-38-42-217-50-54-223-62-66-229-74-77-234-83-85-238-91-93-242-99-101-246-107-109-250-115-117-254-123-125-258-131-133-262-137-135-260-129-127-256-121-119-252-113-111-248-105-103-244-97-95-240-89-87-236-81-79-232-71-69-226-59-57-220-47-45-214-35-33-208-7)184-159(195)144-190-143-152(186-187-190)145-264-173(207)183-155(13-9-10-25-176-158(194)22-29-210-37-41-216-49-53-222-61-65-228-73-76-231-68-64-225-56-52-219-44-40-213-32-28-191-162(198)20-21-163(191)199)168(202)185-165(147(3)4)170(204)182-154(15-12-27-178-172(175)206)167(201)180-151-17-19-157(193)149(140-151)142-189(6)161(197)24-31-212-39-43-218-51-55-224-63-67-230-75-78-235-84-86-239-92-94-243-100-102-247-108-110-251-116-118-255-124-126-259-132-134-263-138-136-261-130-128-257-122-120-253-114-112-249-106-104-245-98-96-241-90-88-237-82-80-233-72-70-227-60-58-221-48-46-215-36-34-209-8/h16-21,139-140,143,146-147,153-155,164-165,192-193H,9-15,22-138,141-142,144-145H2,1-8H3,(H,176,194)(H,179,200)(H,180,201)(H,181,203)(H,182,204)(H,183,207)(H,184,195)(H,185,202)(H3,174,177,205)(H3,175,178,206)/t153-,154-,155-,164-,165-/m0/s1
|
|||||
| InChIKey |
JOHHMAKEWNUCFZ-UTAHIYBCSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
3812.452
|
Polar area
|
1018.32
|
||
|
Complexity
|
.
|
xlogp Value
|
0.1975
|
|||
|
Heavy Count
|
264
|
Rot Bonds
|
206
|
|||
|
Hbond acc
|
76
|
Hbond Donor
|
14
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
CD74 Milatuzumab DANAPAE152C S375C-P1-L30-P2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.238 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L30-P2 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||